

# CORPORATE NEWS

MeVis Medical Solutions AG  
Caroline-Herschel-Straße 1  
28359 Bremen  
Germany

Phone: +49 421 224 95 0  
Fax: +49 421 224 95 999  
E-mail: [ir@mevis.de](mailto:ir@mevis.de)

## MeVis Q2 2015: Revenues benefit from strong US dollar

### Significant increase in revenues from strong US dollar, at the same time slightly weaker results

- Sales in the second quarter increased by 15 % to €3.7 m due to the strong US dollar (prev. year: €3.2 m)
- Earnings before interest and taxes (EBIT) decreased to €1.6 m (prev. year €1.8 m), EBIT margin of 23 %
- Net profit declined to €1.3 m (prev. year €1.7 m)
- Liquidity of €21.6 m as at June 30, 2015 (Dec. 31, 2014: €17.5 m)

**Bremen, August 11, 2015** – MeVis Medical Solutions AG [ISIN: DE000A0LBF4], a leading provider of medical imaging software, today announced its results for the first half of 2015.

Sales in the second quarter of 2015 came to € 3,730 k, 15 % higher than in the second quarter of 2014 (€ 3,234 k) and surpassing the first quarter of 2015 (€ 3,408 k). At € 7,138 k, sales in the first half of the year increased considerably year on year (prev. year: € 6,062 k). The growth in sales is entirely attributable to the US dollar exchange rate, which contributed € 1,145 k to sales growth in the half year. Revenues generated from licensing business increased by 8 % to T€ 3,326, revenues from maintenance business increased by 11 % to T€ 3,080, accounting for 43 % of total sales. Sales in the Digital Mammography segment increased by 19 % to €5,637 k (prev. year: €4,738 k) and sales in the Other Diagnostics segment increased by 13 % to €1,501 k (prev. year: €1,324 k).

*Sales increased year-on-year by 15 %, though entirely attributable to the US\$ development*

Staff costs increased in the second quarter according to plan by 2 % to € 1,798 k (prev. year: € 1,755 k), resulting in an identical increase of 2 % (from € 3,567 k to € 3,635 k) for the first half of the year. Other operating expenses fell in the second quarter by 19 % to € 453 k (prev. year: € 559 k), but increased by 3 % cumulative in the first half of 2015.

*Staff costs and other operating expenses increased slightly as planned*

The capitalization of development expenses was ceased in the fourth quarter of 2014 (prev. year: € 841 k).

Due to increased sales and despite the cessation of the capitalization of development expenses, MeVis sees a slight increase of the EBITDA (earnings before interest, taxes, depreciation and amortization) by 2 %, from € 2,605 k to € 2,667 k.

After depreciation and amortization of € 1,040 k (up 27 % year on year), this results in an EBIT (earnings before interest and taxes) of € 1,627 k (with 9 % well below the previous year's figure of € 1,789), corresponding to an EBIT margin of 23 % (prev. year: 30 %).

*EBIT significantly lower than prior year, margin of 23 %*

The net financial result improved by € 271 k to € 428 k year on year. Mainly the development of the US\$ exchange rate and the improvement of the MeVis BreastCare have contributed to this. Income tax expenses increased by € 568 k to € 787 k, which results mostly from deferred taxes.

Net profit fell by € 459 k to € 1,268 k, which is equivalent to undiluted earnings per share of € 0.72 (prev. year: 1.00).

*Earnings per share (undiluted) of € 0.72*

Cash and cash equivalents increased by € 4,052 k to € 21,563 k as of June 30, 2015 compared to the end of 2014. This includes € 1,707 k from the sale of treasury shares to the VMS Deutschland Holdings GmbH in April 2015.

The Company's financial reports can be downloaded from the following website:

<http://www.mevis.de/en/investor-relations/financial-reports/>

\*\*\*\*\*

*MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.*

*Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.*